AU Patent

AU2018202991B2 — CDK Inhibitors

Assigned to Pharmacosmos Holding AS · Expires 2020-02-13 · 6y expired

What this patent protects

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

USPTO Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018202991B2
Jurisdiction
AU
Classification
—
Expires
2020-02-13
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacosmos Holding AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.